Technology · Health & biomedicine / Therapeutics & platforms

NK-cell & CAR-NK therapy

CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform.

Maturity 4/9 Risk: medium Advanced therapies US · CN · EU Science: why it works → verified 2026-06-19 · 0 Sources (0 independent)

1 · What it gives

NK-cell therapy (Natural Killer) and CAR-NK use innate effector cells to kill tumors. Unlike autologous CAR-T, NK cells are allogeneic, “off-the-shelf”: donor- or iPSC-derived, with no GVHD risk and minimal CRS. CAR-NK carries a chimeric antigen receptor (e.g. anti-CD19 or NCG2D) for tumor-antigen recognition. The iPSC-NK platform (Fate Therapeutics) yields scalable, standardised batches from a single cell line. Early-clinical responses reach 60–80% in haematological cancers, with a better toxicity profile than CAR-T.

Key platforms of NK therapy:

CAR-NK (CAR-NK): NK with a CAR (anti-CD19, NKG2D) — directed cytotoxicity.
iPSC-NK (iPSC-derived NK): standardised NK from induced pluripotent stem cells — scale.
Cord-blood NK (Cord-blood NK): donor NK from umbilical-cord blood (Takeda/MD Anderson).
NK engagers (NK-cell Engagers): bispecifics linking NK to tumor (Affimed).

Sectoral value chain#

[donor/iPSC line] ──> [NK manufacture + expansion] ──> [CAR transduction (optional)]
                                                              │
                                                  (cryopreservation / QC)
                                                              │
                                                              ▼
[patient] <─── [off-the-shelf infusion] <─── [allogeneic dose release]

Value chain levels#

Level	Description	Key inputs/outputs
Cell Source	iPSC line or donor cord blood	In: iPSC/blood. Out: cell source.
NK Differentiation/Expansion	NK differentiation/expansion (14–21 days)	In: source, cytokines. Out: NK pool.
CAR Engineering	lentiviral CAR transduction (optional)	In: NK pool, vector. Out: CAR-NK.
Fill & Cryostore	fill, cryopreserve off-the-shelf doses	In: CAR-NK. Out: cryobanked doses.
Infusion (Off-the-shelf)	thaw and infuse without patient lymphodepletion	In: dose, patient. Out: infused patient.
Follow-up	response, CRS, NK persistence monitoring	In: patient. Out: therapy outcome.

Cross-cutting technologies of the sector:

iPSC platform (iPSC Platform): standardised, scalable NK batches from one line.
Off-the-shelf: ready doses — no autologous-manufacturing delay (vs CAR-T).
NK-cell engagers: bispecifics (Affimed) — link NK to tumor without a CAR.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

1
Cell source
An iPSC line or donor umbilical-cord blood as the starting material.
2
NK expansionFermentation & cultivation
NK differentiation/expansion with cytokines (IL-2, IL-15) over 14–21 days.
Who can do this step matched automatically
Esco Aster Singapore
✓ ISO 9001 5,000 L industrial scale
“TideMotion® Bioreactors”
PBS Biotech United States
✓ ISO 9001 industrial scale
“PBS Biotech is advancing the future of cell therapy manufacturing through innovative, single-use bioreactor solutions designed specifically for shear-sensitive cell cultures.”
Bota Bio 恩和生物 China
✓ ISO 9001 600 tons pilot scale
“Bota Biosciences is a global leader in Physical AI-driven biomanufacturing, dedicated to making biotechnology a reliable and scalable engine of productivity.”
CHITOSE Japan
industrial scale
“AI x BIOMANUFACTURING”
Pensées South Korea
pilot scale
“We have developed a high-efficiency bioreactor specifically for cultured meat production and have secured safety and cost-effectiveness by developing a medium using food-grade …”
Unibio Denmark
industrial scale
“Unibio is a leading biotechnology company specialising in advanced gas fermentation technology.”
3
CAR transduction (optional)
Lentiviral CAR transduction (anti-CD19/NKG2D) for CAR-NK.
4
Fill & cryopreservation
Filling into doses, cryopreservation of the ready allogeneic product.
5
Dose release
Quality control (sterility, viability, potency); release of the ready dose.
6
Infusion
Thaw and infusion to the patient (off-the-shelf, often without deep lymphodepletion); response and NK-persistence monitoring.

4 · Who delivers

Matched suppliers (matched automatically)

PBS Biotech	United States	Services / consulting	active
Esco Aster	Singapore	Services / consulting	active
ImpacFat	Singapore	Producer	active
Integriculture	Japan	Equipment	active
Simple Planet	South Korea	Producer	active
Unibio	Denmark	Producer	active
CellMEAT	South Korea	Producer	active
Pensées	South Korea	Producer	active
Sartorius	Germany	Producer	active
Aleph Farms	Israel	Producer	active

Leading companies and institutes (from the brief)

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Nkarta	🇺🇸 USA	NKX101 (NKG2D CAR-NK)	phase I AML	Scaling
Fate Therapeutics	🇺🇸 USA	iPSC-NK platform	standard batches from iPSC	Scaling
Takeda	🇯🇵 Japan	CD19-CAR-NK (with MD Anderson)	cord-blood, phase II lymphoma	Scaling
Artiva Biotherapeutics	🇺🇸 USA	allogeneic NK (AB-101)	off-the-shelf cord-blood doses	Scaling
Affimed	🇩🇪 Germany	NK-cell engagers (ICE®)	CAR-free bispecifics	Scaling
MD Anderson	🇺🇸 USA	academic CAR-NK	CD19-CAR-NK with Takeda	Research

5 · Rules & route to market

United States

The US leads CAR-NK design on an iPSC base (Fate, Nkarta), with NCI support.

Fate Therapeutics, Nkarta, NCI funding#

Fate Therapeutics: iPSC-NK platform — standard batches from a single line.
Nkarta: NKX101 (NKG2D CAR-NK) — phase I in acute myeloid leukaemia.
NCI: grants for fundamental and translational NK research.

European Union

The EU is strong in allogeneic platforms and NK-cell engagers.

Affimed engagers, EMA ATMP, academic NK programs#

Affimed (Germany): bispecific NK-cell engagers (ICE®) — link NK to tumor.
EMA ATMP: allogeneic NK classified as ATMP; strict donor oversight.
Academic programs: university NK protocols (Germany, Netherlands).

China

China is rapidly adopting CAR-NK in solid and haematological cancer trials.

Clinical scale-up, NMPA pathway, domestic platforms#

Clinical experience: CAR-NK in hepatocellular carcinoma and lymphomas.
Domestic platforms: local CAR-NK developers under NMPA.
NMPA: accelerated pathways for strategic cell-therapy candidates.

6 · Money: tenders & grants

Grant	Advancing bio-printing of living cells for regenerative medicine European Commission · EU	Sep 22, 2027 341 days
Grant	Strengthening evidence-based policies for the resilience of European agriculture and forestry and related … European Commission · EU	Sep 23, 2027 342 days

7 · Tech stack & innovations

The stack rests on iPSC-NK, off-the-shelf logistics and engagers.

iPSC-NK (iPSC-derived NK):
- standardised NK from a single iPSC line — scalable batches.
Off-the-shelf:
- cryobanked ready doses — infusion without autologous-manufacturing delay.
NK-cell engagers:
- bispecific molecules (Affimed ICE®) link NK to tumor without engineering the cell.